《異動股》國泰/國航/南航探頂 米蘭站飆四成
雖然本港新冠肺炎疫情嚴峻,但英國將於下周率先為當地高危人群接種輝瑞與德國藥廠BioNTech研發的新冠肺炎疫苗,市場憧憬疫苗短期內於全球面世。本港航空股造好,尤其是國泰航空(00293.HK)三連漲,最高見7.74元,創近半年高,現造7.72元,續升3.6%,成交增至952萬股。國泰持股逾18%的國航(00753.HK)也三連漲兼屢探頂,最高見6.8元,創近九個月高,現造6.67元,續升1.7%。東航(00670.HK)及南航(01055.HK)高見3.68元及5.13元,現造3.66元及5.12元,回升3.1%及4.3%,後者創逾十個月高,成交分別增至2,010萬股及2,757萬股。
此外,米蘭站(01150.HK)三連漲,今天股價更發力突破牛熊線(0.176元),最高見0.23元,現造0.191元,急升40%,成交激增至6,176萬股,為逾三年罕見。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.